Skip to main content

Heart Failure-MERCK 1242-001 (VICTORIA)

The primary aim of this study is to increase the time to first occurrence of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with reduced heart ejection fracture.

Sponsor: Merck Sharp & Dohme Corp.

Phase: 3

Indication: Heart Failure

Age: 18 years or older

Category: Interventional

For more information:

Studies Currently Available At

Sign Up For This Study